polidocanol and bleomycetin

A meta-analysis was conducted to investigate the efficacy and safety of polidocanol versus other conventional therapies in treating hemangiomas (HMs) and vascular malformations (VMs). Literature search was conducted in the Cochrane, Embase, PubMed, Web of Science, CNKI, CBM, VIP, and WanFang databases until March 5, 2017. A meta-analysis was conducted using Revman 5.3 software. A total of 19 randomized controlled trials (RCTs) involving 1,514 participants met the inclusion criteria. Regarding the effectiveness, statistically significant differences were observed between polidocanol and all the independent treatments (p = .006), but not between polidocanol and pingyangmycin (p = .16). Combination therapy of polidocanol with any other conventional treatments (p = .0001), pingyangmycin (p = .005) or hemoclip (p = .008) elicited a better response compared to treatment with these treatments independently. A meta-analysis on the risk of adverse events (AEs) showed a lower risk for polidocanol versus other treatments, for example, all the conventional treatments used independently (p < .00001) and pingyangmycin (p < .00001). Combination therapy of polidocanol with pingyangmycin also yielded a significantly lower risk of AEs (p < .00001). Polidocanol is at least as effective as other conventional therapies on HMs and VMs (especially venous malformations). The former is much safer. Combining its use with other treatments may produce excellent results. Our study provides strong evidence supporting the use of polidocanol for HMs and VMs.

Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Bleomycin; Chi-Square Distribution; Child; Child, Preschool; Female; Hemangioma; Humans; Infant; Infant, Newborn; Male; Middle Aged; Odds Ratio; Polidocanol; Polyethylene Glycols; Randomized Controlled Trials as Topic; Risk Factors; Sclerosing Solutions; Sclerotherapy; Treatment Outcome; Vascular Malformations; Young Adult

To compare the clinical efficacy of pingyangmycin and lauromacrogol combined with pingyangmycin in the treatment of venous malformations (VMs).. One hundred and twenty patients with VM were randomly divided into lauromacrogol combined with pingyangmycin injection group (experimental group) and pingyangmycin injection group (control group). The appropriate interval between different injection sessions was 2 weeks. After different sessions, the changes of lesions (including size, color, texture) as well as the results of posture test and adverse effects were analyzed by using SPSS11.5 software package.. According to the international evaluation criteria for VM, the efficacy of the experimental group was significantly better than the control group after 2~5 sessions (P<0.05). However, after 1 and 6 sessions, there was no significant difference in the efficacy between the experimental group and the control group (P>0.05). In addition, the average sessions required in the experimental group were significantly less than those in the control group (P<0.05).. Compared to the single use of pingyangmycin, lauromacrogol combined with pingyangmycin is more effective for the treatment of VM, with fewer sessions required and no adverse effects.

Topics: Bleomycin; Color; Female; Humans; Injections, Intralesional; Male; Polidocanol; Polyethylene Glycols; Posture; Sclerotherapy; Treatment Outcome; Vascular Malformations; Veins

Topics: Humans; Lymphangioma; Lymphangioma, Cystic; Lymphatic Abnormalities; Polidocanol; Retrospective Studies; Sclerosing Solutions; Sclerotherapy; Treatment Outcome

To investigate the clinical effect of radiofrequency ablation (RFA) combined with lauromacrogol for the treatment of parotid gland hemangioma in infants.. From Sep.2005 to Dec.2014,a total of 117 patients with parotid gland hemangioma were divided into observation group (n =32),control group 1 (n =30),control group 2 (n =28) and control group 3 (n =27).The observation group was treated by RFA combined with lauromacrogol, while the control group 1 was treated by RFA only, the control group 2 was treated by pingyangmycin only, and the control group 3 received additional pingyangmycin based on RFA. All the patients were followed up for 6 to 24 months, and the clinical effects were observed in four groups.. Control group 1:16 patients were cured (53.3％),and the number of patients with ≥2 treatments was 9.There was 1 case with skin ulceration,1 with abdominal discomfort,1 with liver function damage and 1 with high fever.Control group 2:17 patients were cured(60.7％),and number of patients with ≥2 treatments was 12.There were 3 cases with skin ulceration,9 with abdominal discomfort,6 with liver function damage and 5 with high fever.Control group 3:21 patients were cured(77.8％),and number of patients with ≥2 treatments was 2.There were 2 cases with skin ulceration,6 with abdominal discomfort,4 with liver function damage and 4 with high fever.However,in observation group,25 patients were cured(78.1％) and number of patients with ≥ 2 treatments was 4,which were significantly different from that in control group 1 or control group 2 (P ＜0.05).And the difference in postoperative adverse reactions between observation group and control group 2 or control group 3 was also of significance (2 with skin ulceration,1 with abdominal discomfort,1 with liver function damage and 6 with high fever,P ＜ 0.05).. Combined RFA and lauromacrogol has a good therapeutic effect on parotid gland hemangioma with relatively low adverse effect, so it deserves to be suggested and applied in clinical practice.

Topics: Antibiotics, Antineoplastic; Bleomycin; Catheter Ablation; Female; Hemangioma; Humans; Infant; Male; Parotid Gland; Polidocanol; Polyethylene Glycols; Treatment Outcome